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Abstract: In patients with previously-untreated, completely-re-
sected pathologic stage II–III non-small cell lung cancer, 4 months
of postoperative cisplatin-based chemotherapy reduces the risk of
death by approximately 20%. To date, the only prospectively vali-
dated prognostic and predictive factor which can be used to guide
clinical practice is pathologic stage. Higher stage patients have a
worse prognosis, but derive more benefit from adjuvant chemother-
apy. Numerous molecular markers are being developed with the
potential to help decide which patients to treat with adjuvant che-
motherapy, and which drugs to use. This paper will review the
molecular markers which are having immediate impact on treatment
decisions in routine practice, and which merit further study in the
next generation of adjuvant chemotherapy trials.
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Nonsmall cell lung cancer (NSCLC) is the major cancerkiller worldwide, accounting for more than 1.2 million
deaths each year. NSCLC is deadly because it is usually a
systemic disease at the time of presentation. Even after
complete surgical resection of stage I–III NSCLC, approxi-
mately half of patients will recur and die within 5 years
because of unrecognized micrometastatic disease.1 Recent
clinical trial data demonstrate that 4 months of cisplatin-
based adjuvant chemotherapy improves survival in patients
with stage IB–III NSCLC after complete resection.2–4
The data in favor of adjuvant chemotherapy for patients
with resected NSCLC have limitations. The clinical trials
randomized fewer than 5000 patients with a median fol-
low-up of 5 years. In comparison, adjuvant therapy for breast
cancer is guided by data from more than 110,000 patients
with more than 15 years of follow-up.5 Historically, the study
of adjuvant chemotherapy in NSCLC has been hampered by
nihilism from past negative trials, difficulties delivering che-
motherapy to patients after thoracotomy, and the fact that
lung cancer patients are older (median age 70 in the United
States), and have higher rates of comorbid medical illnesses
related to cigarette smoking than other cancer patients.
The patients enrolled in the positive clinical trials were
mostly younger (median age 60), had high-risk NSCLC
(stage IB–III), good performance status, and could safely
receive cisplatin.2–4 In the real world, oncologists see
NSCLC patients who are generally older, with clinical or
pathologic characteristics which may have excluded enroll-
ment on the pivotal trials. For example, there is currently no
data to support the use of adjuvant chemotherapy in patients
with stage IA NSCLC, little support for treating IB patients,
no data for stage II–III patients who are not candidates for
cisplatin, or stage IV patients rendered disease-free by sur-
gery. There is no data to support chemotherapy in patients
with a positive surgical margin, patients with pure bronchi-
oloalveolar subtype, or for patients aged more than 75 years.6
All patients in previous randomized trials began their chemo-
therapy within 2 months of their date of surgery, so there is
no data to support starting chemotherapy more than 2 months
postoperatively. Outside of studies of oral fluoropyrimidines
conducted in Japan, there are no data to support noncisplatin-
based adjuvant chemotherapy.7,8
For patients who do not fit the profile of those enrolled
on the prior clinical trials, there are no data supporting
adjuvant chemotherapy. One might consider treating border-
line patients (stage I, stage IV, or any patient aged75 years)
except for the substantial risks of adjuvant chemotherapy.
Cisplatin-based adjuvant chemotherapy causes side effects
including venous irritation from vinorelbine (20–30%), de-
bilitating fatigue (15–28%), nausea (10–27%), anorexia (10–
15%), anemia (7–14%), infection (1–11%), febrile neutrope-
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nia (7–9%), hair loss (0–5%), peripheral neuropathy (3%),
and a risk of treatment-related death (1–2%).2,4 As a result,
half of the patients drop out before completing all 4 months
of chemotherapy.
What should the oncologist recommend for a young, fit
patient with a 2.8 cm tumor (borderline IB), or an elderly
patient with resected stage III NSCLC who is unlikely to
tolerate cisplatin? Identification of biomarkers beyond patho-
logic stage could help inform the oncologist as to which
patients to treat, and which agents to use.
CLINICAL PROGNOSTIC AND PREDICTIVE
FACTORS
Prognostic factors predict outcome (usually survival)
independent of the treatment administered, and can be used to
classify patients as high-risk, or low-risk. Predictive factors
predict response of the tumor to treatment, usually in terms of
tumor shrinkage, or survival benefit from treatment.
To date, pathologic stage is the only prospectively
validated prognostic and predictive clinical factor for pre-
scribing adjuvant chemotherapy for NSCLC. A meta-analysis
of data from more than 5000 patients randomized to cisplatin-
based adjuvant chemotherapy versus surgery alone (Lung
Adjuvant Cisplatin Evaluation), demonstrated that higher
stage patients garner more benefit from adjuvant chemother-
apy.9 Patients with stage II–III disease clearly benefit from
chemotherapy (hazard ratio [HR], 0.83; 95% confidence in-
terval [CI], 0.73–0.95). There is less benefit seen in patients
with stage IB disease (HR, 0.92; 95% CI, 0.78–1.10), and
potential for harm in patients with stage IA disease (HR, 1.41;
95% CI, 0.96–2.09).
Therefore, stage is the most important factor to con-
sider when prescribing adjuvant chemotherapy. The higher
the stage, the worse the prognosis, and the more likely
adjuvant chemotherapy may be beneficial (Figure 1). Other
prospectively validated clinical factors which suggest better
prognosis include young age, squamous histology in early-
stage patients (IB–II), and whether the patient received adju-
vant chemotherapy.2–4 Other than stage, there are no clinical
factors which predict which patients will benefit more from
adjuvant chemotherapy (Table 1).
MOLECULAR PROGNOSTIC AND PREDICTIVE
FACTORS
Patients who have undergone resection of NSCLC usually
have adequate tissue for molecular analysis. Rapid advances in
technology have lead to high-throughput assays to measure
changes in NSCLC DNA, RNA, and proteins so as to identify
potential molecular biomarkers of clinical outcome. The discov-
ery of molecular markers of potential significance, and refine-
ments in molecular assays, will likely outstrip our ability to test
all of them in prospective clinical trials. Almost all current
molecular markers of interest have been developed using tissue
banks, and retrospective cohort studies (Table 2).
Kirsten Rat Sarcoma Viral Oncogene Homolog
(KRAS)
The only molecular marker which has been studied pro-
spectively in a randomized trial of adjuvant chemotherapy is
mutation in rat sarcoma viral oncogene (RAS). RAS is an
enzyme (GTPase) which transmits growth signal by binding to,
and hydrolyzing guanosine triphosphate. RAS is downstream of
the growth signal transmitted into a cell by the epidermal growth
factor receptor (EGFR). Three human RAS genes have been
identified—HRAS (Harvey), KRAS (Kirsten), and NRAS (neu-
roblastoma)—each of which is highly homologous. RAS mu-
tations are detectable in approximately 20% of lung cancers, are
found more often in cigarette smokers, and have been associated
with a poor prognosis in several studies.10–15 KRAS mutations
constitute 90% of all RAS mutations in NSCLC. More than 80%
of KRAS mutations occur in codon 12, whereas other mutations
are located in codons 13 and 61.
In the National Cancer Institute of Canada JBR-10 adju-
vant trial, 482 patients with completely resected stage IB to IIB
NSCLC were analyzed for RAS mutations.2 Participating cen-
ters submitted fresh-frozen primary tumor or paraffin-embedded
blocks of tissue specimens to a central laboratory for RAS
mutation analysis of codons 12, 13, and 61 of the HRAS, KRAS,
FIGURE 1. Patients with higher stage NSCLC
have a worse prognosis, and are more likely to
benefit from adjuvant chemotherapy. This is a
graphical representation of 100 patients with re-
sected NSCLC, grouped by stage, all of whom
receive 4 months of postoperative cisplatin-
based chemotherapy. Some patients die de-
spite chemotherapy, others live due to surgery
alone, and some others live due to the chemo-
therapy. The numbers for this figure are based
on the hazard ratio (HR) from the Lung Adju-
vant Cisplatin Evaluation meta-analysis, and
5-year survival from the Adjuvant Navelbine
International Trialist Association (ANITA) trial.4,9
Graphs such as these may be generated for
individual patients on a Web-based resource
for health professionals and patients: Adjuvant!
On-line (www.adjuvantonline.com).
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and NRAS genes by allele-specific oligonucleotide hybridiza-
tion. The RAS mutations found were confirmed by direct se-
quencing. The status of RAS mutations in the tumors was able
to be determined in 450 patients (93%), with 24% of these
patients found to have a RAS mutation in their tumor. Patients
were prospectively stratified by the presence of RAS mutation,
allowing retrospective subgroup analysis.
The median survival among patients with wildtype
RAS in the observation group was 74 months and was not
reached in the group that received chemotherapy (HR, 0.69;
95% CI 0.49–0.98; p  0.03). However, for patients whose
tumors harbored a RAS mutation, adjuvant chemotherapy did
not confer a survival advantage (HR, 0.95; 95% CI 0.53–
1.71; p  0.87). In an interaction analysis, the effect of the
status of RAS mutations on the outcome of treatment was not
statistically significant (p  0.29), and RAS was not an
independent predictor of survival in this study. However, the
lack of demonstrable benefit of adjuvant cisplatin plus vinorel-
bine chemotherapy in RAS-positive patients in this study, de-
spite the large benefit seen overall in this trial, suggests that
patients with a RAS mutation should not be offered postopera-
tive cisplatin plus vinorelbine chemotherapy.
EGFR
EGFR—also known as human epidermal growth factor
receptor 1 (HER1), or avian erythroblastic leukemia viral
TABLE 1. Clinical Factors with Prognostic and Predictive Value
Prognosis Prediction Level of Evidencea
Higher stage (T, N, M) Worse ?b I
Male sex Worse Lower chance of responding to EGFR tyrosine kinase inhibitors I
Performance status Worse Lower chance of responding to chemotherapy I
15% weight loss Worse ? I
High comorbidity score Worse ? II
Smoking (15 py) Worse Lower chance of responding to EGFR tyrosine kinase inhibitors II
Asian ethnicity ? Higher chance of responding to EGFR tyrosine kinase inhibitors II
High serum LDH Worse ? II
High serum calcium Worse ? II
Low blood hemoglobin Worse ? II
Low serum albumin Worse ? II
Squamous histology (N0–1) Better ? II
a Level I evidence has been validated by data from a prospective, randomized trial. Level II evidence is based on retrospective cohort studies.
b Clinical trials of neoadjuvant chemotherapy for stage I-III NSCLC demonstrate higher radiologic response rates (50–70%) than trials of palliative chemotherapy for stage
IIIB-IV NSCLC (20–30%). It is not known whether there is a difference in radiologic response rate between stage I, II and III NSCLC.
EGFR, epidermal growth factor receptor; LDH, lactate dehydrogenase.
TABLE 2. Molecular Tests with Prognostic and Predictive Significance
Prognosis Prediction Level of Evidencea
EGFR mutation (exon 19 deletion v. exon
21 missense)
Better Higher chance of responding to EGFR tyrosine kinase
inhibitors
II
EGFR amplification Better Higher chance of responding to EGFR tyrosine kinase
inhibitors
II
EGFR IHC positive Worse Higher chance of responding to EGFR tyrosine kinase
inhibitors
II
KRAS mutation Worse No benefit from adjuvant cisplatin  vinorelbine, lower
chance of responding to EGFR tyrosine kinase inhibitors
II
ERCC1 IHC positive Better No benefit from adjuvant cisplatin-based chemotherapy,
less responsive to cisplatin
II
RRM1 IHC positive Better Less responsive to gemcitabine II
p27 IHC positive Better No benefit from adjuvant cisplatin-based chemotherapy II
ERCC1 and p27 “double-positive” by IHC Better No benefit from adjuvant cisplatin-based chemotherapy
ERCC1 and RRM1 “double-positive” by AQUA Better Less responsive to cisplatin and gemcitabine
MRP2 IHC positive Worse ? II
FasL-negative by IHC ? More benefit from cisplatin-based adjuvant
chemotherapy
II
High bTubIII by IHC Worse More benefit from adjuvant cisplatin  vinorelbine II
“High-Risk” gene expression profile (various platforms) Worse ? II
a Level I evidence has been validated by data from a prospective, randomized trial. Level II evidence is based on retrospective cohort studies.
EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homolog; ERCC1, excision repair cross-complementation group 1; RRM1, ribonucleotide
reductase subunit 1; MRP2, multidrug resistance protein 2; FasL, ligand for tumor necrosis factor receptor superfamily member 6; bTubIII, class III beta-tubulin.
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oncogene homolog (ErbB1)—is a signaling protein attached
to the cell membrane that transmits growth signals into the
cytoplasm through a tyrosine kinase which is activated when
the receptor binds to growth factors. The anticancer drugs,
erlotinib and gefitinib, are small molecule inhibitors of the
EGFR tyrosine kinase. Erlotinib is currently approved as a
second-, or third-line chemotherapy for patients with meta-
static NSCLC based on a prospective trial showing an im-
provement in overall survival versus placebo.16 In 10% of
patients with radiologic response to erlotinib, the median
duration of response was 8 months. For all patients treated
with erlotinib, median overall survival was 7 months com-
pared with 5 months with placebo (HR, 0.70; p  0.001).
In 2004, three groups of investigators independently
discovered that mutations in the tyrosine kinase domain of
EGFR are strongly associated with sensitivity to erlotinib and
gefitinib.17–20 These mutations are almost never found in
NSCLC with squamous histology, but occur in approximately
10% of adenocarcinomas. Patients with EGFR mutant tumors
live longer than patients with EGFR wildtype tumors, regard-
less of the treatment. In one retrospective study, patients with
metastatic NSCLC and no EGFR mutation had a median
survival of 10 months, while the median survival of patients
with EGFR mutation was not reached.21 The superior out-
come of patients with NSCLC and EGFR mutation in this
study confounded Kaplan-Meier analysis of survival given
that so few deaths were observed in these patients.
The different types of EGFR mutations have different
prognostic values. Patients with EGFR mutations character-
ized by deletion in exon 19 have a better prognosis than
patients with missense mutations in EGFR exon 21.22,23 In
one retrospective study of 34 patients with EGFR mutation
treated with erlotinib or gefitinib, patients with EGFR exon
19 deletions had significantly longer median survival than
patients with EGFR L858R mutations (34 versus 8 months;
log-rank p  0.01).23
There are numerous, prospective, single-arm clinical
trials which suggest that erlotinib or gefitinib are highly
active treatments for patients whose lung tumors harbor an
EGFR mutation.24–27 Whereas it is well-established that the
presence of an EGFR mutation may increase responsiveness
of NSCLC to erlotinib or gefitinib, these same mutations
predict longer survival, regardless of therapy, which may
confound detection of the effect of treatment on overall
survival. As such, there is ongoing debate about which EGFR
biomarker—mutation, gene amplification, or protein overex-
pression—is more important to determine prognosis, and to
predict benefit from treatment with erlotinib and gefitinib.28,29
To date, there are no prospective, randomized studies to
prove that erlotinib or gefitinib improves survival in patients
with metastatic NSCLC and an EGFR mutation. A retrospec-
tive study of patients enrolled in a placebo-controlled trial of
erlotinib found that EGFR gene copy number was a better
predictor of survival benefit from erlotinib than EGFR muta-
tion.28 These data have been criticized due to the potential high
false-positive rate of EGFR mutations, and small subgroup of
patients studied (197 tissue samples from 731 patients on the
trial), which may have confounded this analysis.
Subgroup analyses from several trials of gefitinib and
erlotinib in patients with metastatic NSCLC have confirmed that
patients with NSCLC who have never smoked cigarettes benefit
from these drugs more than patients who smoke,16,30,31 and
never smokers are much more likely to have EGFR mutations
than former or current smokers.17,32 As a result of this debate,
EGFR mutation analysis, EGFR overexpression by immunohis-
tochemistry (IHC), EGFR amplification analysis by fluorescent,
or chromogenic in situ hybridization (FISH/CISH), and never-
smoking status are all currently being studied in prospective
trials of patients with metastatic NSCLC receiving erlotinib and
gefitinib. Evolving data suggest that tumors with EGFR ampli-
fication are more likely to harbor EGFR mutations, and vice
versa, confounding the comparison between these two molecular
characteristics.
Of note, mutations in KRAS and EGFR are mutually
exclusive. Furthermore, the presence of a KRAS mutation
predicts a lack of benefit from gefitinib and erlotinib.21,33,34
As such, patients whose NSCLC harbors a known KRAS
mutation need not be screened for an EGFR mutation, and
vice versa.
A retrospective analysis of 296 patients who underwent
resection at the Memorial Sloan-Kettering Cancer Center for
stage I–III lung adenocarcinoma using established techniques
identified EGFR and KRAS mutations in tumors from 40
(13%) and 50 (17%) of the patients, respectively. (J. Marks
and W. Pao, personal communication.) No tumor had both
mutations. EGFR mutations were significantly associated
with a history of never smoking, whereas KRAS mutations
were associated with smoking (p  0.005). None of the
patients received gefitinib or erlotinib. After adjustment for
pathologic stage, patients with EGFR mutations displayed a
trend toward longer survival when compared with patients
with KRAS mutations (p  0.11). These data suggest that
EGFR and KRAS mutations define clinically distinct molec-
ular subsets of lung adenocarcinoma.
The RADIANT study (Randomized Double-Blind Trial
In Adjuvant NSCLC with Tarceva) is an ongoing, multi-
center, placebo-controlled phase 3 clinical trial of adjuvant
erlotinib in patients with resected NSCLC which expresses
EGFR by IHC, or demonstrates EGFR amplification by
FISH.35–37 Tissue will be studied for EGFR and KRAS
mutations retrospectively. By allowing enrollment of either
IHC or FISH-positive patients, and checking EGFR and
KRAS mutation status retrospectively, this trial design has
been criticized as failing to enrich the study population with
patients most likely to benefit from erlotinib. As RADIANT
continues, there is a need for smaller, single-arm phase 2
clinical trials of erlotinib or gefitinib as adjuvant chemother-
apy, using alternative entrance criteria, such as EGFR muta-
tions. Much may be learned by comparing the results of these
smaller studies to the treatment arm of RADIANT.
Excision Repair Cross-Complementation Group
1 (ERCC1)
More than 800 resected NSCLC tumors from patients
enrolled in the International Adjuvant Lung Trial (IALT)
have been analyzed retrospectively for the expression of 19
independent genes by routine IHC.3,38 Categories of the 19
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molecular markers include DNA repair genes, drug transport-
ers, signal transduction genes, apoptosis, and cell cycle reg-
ulators. This work is ongoing, and much of the data have not
been reported.
Cisplatin kills cancer cells by binding covalently to
DNA to form adducts, which interfere with normal DNA
replication. This DNA damage may trigger apoptosis in
dividing cells. Nucleotide excision repair is the major path-
way for repairing DNA damaged by cisplatin. ERCC1 is the
rate-limiting enzyme in this repair process. Cancer cells
which overexpress ERCC1 are more likely to have de novo
resistance to cisplatin.
Among 761 tumors assayed in the IALT for ERCC1
expression by immunohistochemistry, 335 (44%) were
scored as positive, and 426 (56%) were scored as negative.39
The absence of ERCC1 was associated with increased benefit
from cisplatin-based adjuvant chemotherapy (test for interac-
tion, p  0.009). Compared with surgery alone, adjuvant
chemotherapy significantly prolonged survival among pa-
tients with ERCC1-negative tumors (HR, 0.65; 95% CI 0.50–
0.86; p  0.002) but not among patients with ERCC1-
positive tumors (HR, 1.14; 95% CI 0.84–1.55; p  0.40).
Among patients who did not receive adjuvant chemo-
therapy, those with ERCC1-positive tumors survived longer
than those with ERCC1-negative tumors (HR, 0.66; 95% CI
0.49–0.90; p  0.009). A multivariate logistic model showed
that the expression of ERCC1 was significantly correlated with
age (p  0.03; less common in patients 55 years of age than
in patients 55–64 years of age), histologic type (p 0.001; less
common in adenocarcinomas than in squamous-cell carcino-
mas), and pleural invasion (p  0.01; less common in the
absence than in the presence of pleural invasion).39
An independent study used an automated, quantitative
method to measure expression of ERCC1—and 2 other
genes, ribonucleotide reductase subunit 1 (RRM1), and phos-
phatase and tensin homolog—in 187 patients who had re-
ceived only surgical treatment for NSCLC.40 The investiga-
tors confirmed that RRM1 expression correlated with the
expression of ERCC1 (p  0.001). There is retrospective
evidence that low RRM1 expression is a poor prognostic
factor in NSCLC.41 In addition, RRM1 is the predominant
cellular determinant of the efficacy of the nucleoside ana-
logue gemcitabine (2,2-difluorodeoxycytidine), an impor-
tant chemotherapy drug used for the treatment of NSCLC
which interferes with ribonucleotide reductase.42,43 In the
study by Zheng et al, the overall survival was more than 120
months for patients with tumors with high expression of
RRM1, and 60 months for those with low expression of
RRM1 (HR, 0.61; p  0.02). Among these 187 patients, the
survival advantage was limited to the 30% of patients with
tumors that had a high expression of both RRM1 and ERCC1.
The clinical relevance of ERCC1 and RRM1 expres-
sion has also been studied extensively in patients with met-
astatic NSCLC. In patients with metastatic NSCLC, ERCC1
expression predicts a lower radiologic response rate to plat-
inum-based chemotherapy, and worse survival.44,45 Prospec-
tive clinical trials have been conducted which assign cispla-
tin, versus noncisplatin chemotherapy based on ERCC1
expression. One study randomized 444 patients with stage IV
NSCLC to blind treatment, versus treatment assigned based
on ERCC1 expression. RNA was isolated from pretreatment
biopsies, and quantitative reverse-transcriptase polymerase
chain reaction was performed to determine ERCC1 mRNA
expression. Patients were randomly assigned in a 1:2 ratio to
either the control or genotypic arm before ERCC1 assess-
ment. Patients in the control arm received docetaxel plus
cisplatin. In the genotypic arm, patients with low ERCC1
levels received docetaxel plus cisplatin, and those with high
levels received a nonplatinum regimen (docetaxel plus gem-
citabine). Of 346 patients assessable for response, objective
response was attained by 53 patients (39%) in the control arm
and 107 patients (51%) in the genotypic arm (P  0.02).46
Another study tested tumor tissue for both ERCC1 and
RRM1, and assigned patients to four different chemotherapy
regimens (with or without cisplatin, and with or without
gemcitabine). Sixty of the 85 patients enrolled underwent
biopsy and gene expression analysis. The overall rate of
major radiologic response was 44%, survival proportion at 1
year was 59%, and median survival time was 13 months,
suggesting that therapeutic decision-making based on RRM1
and ERCC1 gene expression for patients with advanced
NSCLC is feasible and promising for improvement in patient
outcome.47
Given the results in the adjuvant setting, and early
results assigning chemotherapy to patients with metastatic
NSCLC based on ERCC1 status, it is reasonable to conduct
clinical trials which offer noncisplatin chemotherapy to pa-
tients with ERCC1-positive NSCLC. There are plans for a
phase 2 (feasibility) study by the Southwest Oncology Group
to treat patients with adjuvant chemotherapy based on
ERCC1 and RRM1 expressions. Patients with tumors with
low RRM1 and low ERCC1 will receive gemcitabine plus
carboplatin. Patients with low RRM1 and high ERCC1 will
receive gemcitabine with docetaxel (a noncisplatin combina-
tion). Patients with high RRM1 and high ERCC1 will receive
vinorelbine and docetaxel (a nongemcitabine, noncisplatin
combination). Patients with high RRM1 and low ERCC1 will
receive docetaxel and carboplatin.
p27Kip1
The cell cycle regulators measured in IALT tumors
included p27Kip1, p16, cyclin D1, cyclin D3, cyclin E, and
Ki-67.48 Among these six proteins, only p27 staining had
predictive value. p27Kip1—also known as Cdkn1b (cyclin-
dependent kinase inhibitor 1B)—is a cyclin-dependent kinase
inhibitor which has an antiproliferative effect on cells, and
which may protect cells from apoptosis by fostering growth
arrest. Thus, p27 overexpression may impart de novo resis-
tance to cisplatin by allowing the cancer cell to repair cispla-
tin-induced DNA damage. In patients with p27-negative
tumors, cisplatin-based chemotherapy resulted in longer
overall survival compared to controls (HR, 0.66; 95% CI
0.50–0.88; p  0.006). In patients with p27-positive tumors,
overall survival was not different between patients treated
with cisplatin-based chemotherapy and controls (HR, 1.09;
95% CI 0.82–1.45; p  0.54). None of these cell cycle genes
were significantly associated with overall survival in the total
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study population. However, historical data consistently dem-
onstrate that p27-positivity is associated with improved prog-
nosis.49–52 Thus, both ERCC1 and p27 expressions have
parallel prognostic and predictive trends—positive staining
means a better prognosis, and less benefit from cisplatin-
based chemotherapy.
When ERCC1 and p27 staining results are combined,
the predictive values are further increased.38 Patients negative
for both proteins benefit the most from adjuvant chemother-
apy (HR, 0.52, 95% CI 0.36–0.74), whereas patients positive
for both seem more likely to be harmed than helped by
adjuvant chemotherapy (HR, 1.27, 95% CI 0.87–1.84). How-
ever, the staining for ERCC1 and p27 fails to correlate in
nearly half of the patients (42%)—i.e., very often tumors are
positive for one gene, but negative for the other.
Other Potential Biomarkers
Tubulins are a family of globular proteins that make up
microtubules in cells, vital for cell structure, movement,
mitosis, and metabolism (vesicular transport). High expres-
sion of class III beta-tubulin (bTubIII) in advanced NSCLC is
known to correlate with reduced response rates and inferior
survival with antimicrotubule agents. Tumor tissue from 265
of the 482 patients enrolled in the NCIC-JBR.10 trial was
analyzed for bTubIII expression by IHC.53 High bTubIII
expression was associated with poorer survival in patients
treated with surgery alone, but not in patients treated with
adjuvant chemotherapy. The benefits of adjuvant chemother-
apy were greater in high versus low tubulin expressors,
however this interaction did not reach statistical significance.
Multidrug resistance proteins are membrane proteins
which pump foreign molecules (including drugs) out of cells.
Two multidrug resistance proteins (MRP1, MRP2) have been
tested in tissue from IALT.54 MRP2-positive patients (47%)
had a significantly worse prognosis, making it an independent
prognostic factor (HR, 1.37, 95% CI 1.09–1.72, p  0.007).
However, neither MRP1 nor MRP2 had predictive value with
regard to benefit from adjuvant chemotherapy.
Apoptotic markers tested in tissue from IALT include
the death receptor Fas, its ligand FasL, and survivin.55 Fas
(tumor necrosis factor receptor superfamily, member 6), and
the ligand for Fas (FasL), are triggers for both intrinsic and
extrinsic programmed cell death (apoptosis). Survivin is an
inhibitor of apoptosis which regulates chromosome segrega-
tion and cytokinesis during mitosis. Of 773 evaluable cases of
NSCLC from IALT, 73% were Fas negative, 49% FasL
negative, and 46% survivin negative. Fas, FasL, and survivin
scores were not related to prognosis, but the ratio of a Fas to
FasL 1 was related to longer survival (HR  0.72; p 
0.02). There was a trend which suggested that chemotherapy
was more likely to benefit FasL-negative patients (HR 
0.69) as compared to FasL-positive (HR  1.03; p  0.06),
as well as for Fas:FasL ratio 1 (HR  0.51) as compared to
a ratio of 1 (HR  0.80; p  0.05).
Analyses of other biomarkers in tissue from IALT is
ongoing, including mutations of p53, KRAS, and EGFR.38 It
is hoped that all of the results from IALT, including the
promising results measuring ERCC1 and p27, will be vali-
dated in tissue from other adjuvant trial populations, such as
the Adjuvant Navelbine International Trialist Association
trial, and NCIC-JBR-10. Until these biomarkers have been
validated in independent studies, they should not be used as
the sole criteria to deny adjuvant chemotherapy to patients
with completely-resected stage II–III NSCLC who are eligi-
ble for cisplatin. All of the genes mentioned above are
certainly worthy of study in clinical trials, and there may
already be a role for KRAS or ERCC1 to tip the scales in
patients where there is controversy (i.e., a younger patient
with stage I NSCLC, or any patient aged 75 years).
Gene Sets and Expression Arrays
Numerous studies have compared global gene expres-
sion profiles from high-risk and low-risk NSCLC tumors to
identify sets of genes whose coordinate expression pattern
may predict patient outcome.56–65 Both the validity and
reproducibility of microarray-based clinical research have
been challenged due to the potential for spurious results from
multiple testing, or incorrect cross-validation procedures.66
Other ongoing debates include whether overall survival, dis-
ease-free survival, or disease-specific survival are the best
endpoints to use in these analyses, and whether to separate
different histologies (adenocarcinoma from squamous carci-
noma).
There is a disconcerting lack of overlap between the
genes identified in the different experiments, with few or no
genes in common in independent gene signatures. For exam-
ple, of the 260 genes identified in five published gene signa-
tures, only three genes were common to more than one
signature.57 This lack of overlap is also seen in gene expres-
sion signatures for predicting outcome of breast cancer pa-
tients.67 This suggests that several different gene expression
signatures are capable of predicting outcome, and raises the
question of which platform is the most accurate.
Clarity may come from combining datasets to get larger
sample sizes, identifying the biologic processes behind the
different gene expression patterns, or correlating gene expres-
sion profiles with other powerful prognostic or predictive
markers such as EGFR or KRAS mutation, or ERCC1 ex-
pression. The technique for handling tissue and the platform
for measuring gene expression is vital to the results
achieved.68,69 Moving forward, it may be more important to
demonstrate reproducible results using the same platform,
including standardized processing of tissue and RNA expres-
sion measurement, than to reconcile the disparate gene sets
derived from disparate platforms.
Given the number of drugs available for the treatment
of NSCLC, gene expression signatures may ultimately prove
to be more valuable if they carry both prognostic and predic-
tive information. None of the studies of NSCLC gene signa-
tures published to date inform choice of chemotherapy. Early
experiments using lung cancer cell lines with variable sensi-
tivity to different drugs demonstrate the ability to identify
oncogenic pathways which predict which drugs will be more
beneficial for treatment.70 This approach will require valida-
tion in patients with metastatic disease, in whom drug effi-
cacy is immediately apparent, before it can be applied in the
adjuvant setting.
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Pilot Program to Study Molecularly Tailored
Adjuvant Chemotherapy
Given the potential of EGFR mutations, KRAS muta-
tions, and ERCC1 expression in informing adjuvant therapy,
the multidisciplinary Thoracic Disease Management Team at
MSKCC, has developed standardized methods for measuring
these molecular markers in all resected NSCLC specimens
(Table 3). We have established sensitive, nonsequencing-
based polymerase chain reaction assays to detect the common
mutations in EGFR exons 19 and 21, which account for 90%
of EGFR mutations found in NSCLC.71 We are currently
testing all resected lung adenocarcinomas for EGFR muta-
tions in exons 19 and 21 by this polymerase chain reaction-
based assay,71 and KRAS mutation by direct sequencing of
exon 2. We are only testing adenocarcinomas for these
mutations given the low rates of detection of these mutations
in squamous tumors. Genomic DNA for testing can be ex-
tracted from 10 to 15 unstained tumor-bearing slides, paraf-
fin-embedded tissue blocks, or freshly frozen tumor speci-
mens. We are also developing mass-spectrometry-based
methods (Sequenom, Inc., SanDiego, CA) which may prove
to be a more efficient method for identifying point mutations
in tumor DNA.72 Measurement of ERCC1 protein expression
is being performed by IHC on paraffin-embedded NSCLC
tissue using the methods of Olaussen, et al.39
The value of these biomarkers is that they are both
prognostic, to help decide which patients should be offered
adjuvant therapy, and predictive, potentially important in
deciding which treatment to assign. Patients are offered
enrollment in clinical trials of adjuvant therapies based on
their molecular phenotype (Table 4).
Based on available data, cisplatin plus vinorelbine is
the best, and most studied drug regimen for adjuvant treat-
ment of NSCLC. Randomized trials to establish alternative or
superior chemotherapy will require large numbers of patients,
and years of follow-up. Meanwhile, the list of promising
drugs for the treatment of metastatic NSCLC continues to
grow. There is strong retrospective data to suggest that
patients with high ERCC1 expression in their resected
NSCLC should not be offered cisplatin-based adjuvant che-
motherapy, and validation of the efficacy of noncisplatin
regimens is sorely needed.
In collaboration with investigators at the Sidney Kim-
mel Comprehensive Cancer Center at Johns Hopkins,
MSKCC is conducting a phase 2 study of a noncisplatin drug
combination (vinorelbine plus docetaxel) as adjuvant therapy
for patients with NSCLC which expresses ERCC1. This
regimen was chosen based on phase 2 data in patients with
metastatic NSCLC showing efficacy comparable to other
noncisplatin combinations, and toxicities—namely onychol-
ysis and hyperlacrimation—which accompany prolonged ad-
ministration and may be avoided in a fixed course of adjuvant
chemotherapy.73,74 Neutropenia from this regimen is manage-
able with growth factor support.
Similarly, there is a strong argument not to offer stan-
dard adjuvant therapy to patients with NSCLC which harbors
a KRAS mutation, but instead explore RAS-directed thera-
pies. At MSKCC we are conducting a phase 2 study to
document the immunogenicity of GI-4000 (GlobeImmune,
Inc., Louisville, CO), a recombinant, heat-inactivated yeast
(Saccharomyces cerevisiae) engineered to express one of
three mutated RAS oncoproteins.75 In combination with
genomic sequencing of tumors before initiation of immuno-
therapy, this approach has potential for immediate application
to human cancers driven by mutations in KRAS.75
Finally, patients with EGFR exon 19 or 21 mutations in
their resected adenocarcinoma will be offered enrollment in a
clinical trial of erlotinib as adjuvant therapy, based on the
prospective phase 2 data in metastatic NSCLC documenting
very high radiologic response rates in this molecular sub-
group. We plan to compare the efficacy results of our single-
arm trial to the outcomes of patients enrolled in the placebo-
controlled RADIANT trial.
CONCLUSION
Given the pace at which new drugs are being discov-
ered for the treatment of metastatic NSCLC, and the speed at
which faster, cheaper, and more accurate techniques for
molecular analysis of tumor tissue are being developed, it is
likely that a promising molecular test designed to guide a
specific treatment may become obsolete by the time the
approach has been validated in a prospective trial. This is
especially true in the adjuvant setting, where prospective
clinical trials require many years to complete. Progress in this
TABLE 3. NSCLC Tissue Biomarkers Currently Tested by
MSKCC Pathology
EGFR mutations exon 19 and 21 by PCR-based assay71
Exon 19 (length analysis of PCR product)
Exon 21 (Sau96I restriction site)
KRAS mutation by direct sequencing of exon 2 (90% of all mutations are
in KRAS codon 12 and 13)
ERCC1 expression by IHC39
EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral onco-
gene homolog; ERCC1, excision repair cross-complementation group 1.
TABLE 4. Assignment of Adjuvant Chemotherapy at MSKCC Based on Molecular Phenotype
EGFR Mutation RAS Mutation EGFR and RAS Wildtype
ERCC1 IHC positive (3% of patients) vinorelbine  docetaxel
then erlotinib
(7% of patients) vinorelbine  docetaxel
then RAS vaccine
(25% of patients) vinorelbine  docetaxel
ERCC1 IHC negative (7% of patients) cisplatin  vinorelbine
then erlotinib
(13% of patients) cisplatin  vinorelbine
then RAS vaccine
(45% of patients) cisplatin  vinorelbine
EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homolog; ERCC1, excision repair cross-complementation group 1.
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field will require clinical judgment, and rational extrapolation
of retrospective data, including data from patients with met-
astatic NSCLC, given that it would be impossible to antici-
pate or test every new technology, and every clinical situation
in a prospective adjuvant trial.
The current retrospective data are not sufficient to
support the routine use of molecular markers to guide adju-
vant therapy for NSCLC outside of a clinical trial. We await
validation of ERCC1, and p27 in tissue from Adjuvant
Navelbine International Trialist Association and JBR10, and
validation of KRAS and EGFR mutation analysis in IALT.
We also look forward to validation of the usefulness of
adjuvant erlotinib, now being tested in the RADIANT study.
Pathologic stage remains the most important factor to
consider when prescribing adjuvant chemotherapy. The pres-
ence or absence of a molecular characteristic should not be
the sole criterion to withhold adjuvant cisplatin plus vinorel-
bine in patients with completely resected stage II to III
NSCLC who are fit and otherwise eligible to take this
chemotherapy safely. However, for patients in whom the
risk:benefit ratio is less clear—such as patients with stage I
NSCLC, or patients with stage II to III disease who are aged
more than 75 years and where cisplatin may be more dan-
gerous—EGFR mutation testing, KRAS mutation testing, or
ERCC1 expression by IHC, may tip the scales.
Before a molecular test can be adopted for routine
practice, a valid and standardized laboratory technique must
be established. For example, there is recent debate with
regard to the specificity of the monoclonal mouse antibody
(mAb 8F1) which was used to detect ERCC1 in the tumor
tissue from IALT,76 and there is a lack of association between
ERCC1 expression as measured by messenger RNA levels by
reverse-transcriptase polymerase chain reaction, versus pro-
tein expression by IHC.40 Also, there are differing opinions
regarding the most efficient and accurate method for detect-
ing EGFR mutations in tumor DNA.77
Pilot studies of molecularly tailored adjuvant therapy
for patients with resected NSCLC being conducted at
MSKCC and elsewhere will help to validate laboratory tech-
niques for molecular assays, establish the feasibility of this
approach, and serve as a stimulus for others to explore
additional innovations in our management of persons with
resected NSCLC who remain at risk for relapse. These phase
2 data will inform the design of future phase 3 trials in which
novel therapies are assigned on the basis of genetic tests, with
the goal to improve survival for patients with both early-stage
and metastatic NSCLC.
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